Literature DB >> 7957804

Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group.

L M Knudsen1, E Hippe, M Hjorth, E Holmberg, J Westin.   

Abstract

This study describes the occurrence of renal failure among 1353 newly diagnosed cases of multiple myeloma. Renal function was evaluated by serum creatinine concentration in 1353 cases, 31% of whom had renal failure at the time of diagnosis. In 1206 cases an estimation of creatinine clearance was made. When renal failure was defined by using creatinine clearance estimation, 49% had renal failure at the time of diagnosis. Renal failure was present in 24% of patients with an M component of IgG-, 31% of IgA- and 100% of IgD-type. 52% of patients with light chain disease had renal failure. The frequency of renal failure was similar in lambda- and kappa-light chain disease. Patients with a high excretion of Bence Jones protein in the urine (> 10 g/24 h) had renal failure significantly more often than patients with lower excretion. Renal failure was related to advanced disease; 41% of patients with stage III (Durie-Salmon) disease had renal failure. Renal failure was found in 45% of patients with hypercalcaemia. When estimated creatinine clearance was used as a predictor of renal function, the same trends were found as mentioned above. In addition, the proportion of patients with renal failure was found to increase with advancing age.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7957804     DOI: 10.1111/j.1600-0609.1994.tb00190.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  55 in total

1.  Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

Authors:  Christof Scheid; Pieter Sonneveld; Ingo G H Schmidt-Wolf; Bronno van der Holt; Laila el Jarari; Uta Bertsch; Hans Salwender; Sonja Zweegman; Igor Wolfgang Blau; Edo Vellenga; Katja Weisel; Michael Pfreundschuh; Kon-Siong Jie; Kai Neben; Helgi van de Velde; Ulrich Duehrsen; M Ron Schaafsma; Walter Lindemann; Marie José Kersten; Norma Peter; Mathias Hänel; Sandra Croockewit; Hans Martin; Shulamiet Wittebol; Gerard Mj Bos; Marinus van Marwijk-Kooy; Pierre Wijermans; Hartmut Goldschmidt; Henk M Lokhorst
Journal:  Haematologica       Date:  2013-08-30       Impact factor: 9.941

Review 2.  Myeloma light chain cast nephropathy, a review.

Authors:  Insara Jaffer Sathick; Maria Eleni Drosou; Nelson Leung
Journal:  J Nephrol       Date:  2018-05-05       Impact factor: 3.902

Review 3.  Advances in treatment for relapses and refractory multiple myeloma.

Authors:  Tiffany Richards; Donna Weber
Journal:  Med Oncol       Date:  2010-03-06       Impact factor: 3.064

4.  Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).

Authors:  Hannah Tessenow; Madlen Holzvogt; Bruno Holzvogt; Marc Andrea; Simone Heyn; Thomas Schliwa; Maik Schwarz; Thomas Zehrfeld; Cornelia Becker; Christian Pfrepper; Georg Nikolaus Franke; Rainer Krahl; Madlen Jentzsch; Sabine Leiblein; Sebastian Schwind; Marius Bill; Vladan Vucinic; Thoralf Lange; Dietger Niederwieser; Wolfram Pönisch
Journal:  J Cancer Res Clin Oncol       Date:  2017-05-22       Impact factor: 4.553

5.  Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan.

Authors:  Masaharu Tamaki; Hideki Nakasone; Ayumi Gomyo; Jin Hayakawa; Yu Akahoshi; Naonori Harada; Machiko Kusuda; Yuko Ishihara; Koji Kawamura; Aki Tanihara; Miki Sato; Kiriko Terasako-Saito; Kazuaki Kameda; Hidenori Wada; Misato Kikuchi; Shun-Ichi Kimura; Shinichi Kako; Yoshinobu Kanda
Journal:  Int J Hematol       Date:  2018-07-23       Impact factor: 2.490

Review 6.  Light Chain Cast Nephropathy: Practical Considerations in the Management of Myeloma Kidney-What We Know and What the Future May Hold.

Authors:  Sandhya Manohar; Samih H Nasr; Nelson Leung
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

7.  Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.

Authors:  Kevin W Finkel; Eric P Cohen; Anushree Shirali; Ala Abudayyeh
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

8.  The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.

Authors:  Meletios Dimopoulos; Adrian Alegre; Edward A Stadtmauer; Hartmut Goldschmidt; Jeffrey A Zonder; Carlos M de Castro; Zvenyslava Masliak; Donna Reece; Marta Olesnyckyj; Zhinuan Yu; Donna M Weber
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

9.  Possible intrinsic association of anti-neutrophil cytoplasmic antibody-associated vasculitis coexisting with multiple myeloma.

Authors:  Huifang Liu; Jiachuan Xiong; Jun Zhang; Ying Zhang; Ling Nie; Yiqin Wang; Jinghong Zhao
Journal:  Oncol Lett       Date:  2016-07-13       Impact factor: 2.967

10.  Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma.

Authors:  Gaurav C Parikh; Ali Imran Amjad; Rima M Saliba; Syed M A Kazmi; Ziad U Khan; Amit Lahoti; Chitra Hosing; Floralyn Mendoza; Suhail R Qureshi; Donna M Weber; Michael Wang; Uday Popat; Amin M Alousi; Richard E Champlin; Sergio A Giralt; Muzaffar H Qazilbash
Journal:  Biol Blood Marrow Transplant       Date:  2009-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.